Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer

Abroad (travel likely)RecruitingPHASE3

Conditions

Breast Neoplasms · Locally Advanced or Metastatic Breast Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Shusen Wang, Guangzhou, Gangdong, China
Contact: Study coordinator (shusen wang, MD) · wangshs@sysucc.org.cn · +86-020-87342693
Hunan Cancer Hospital, Hunan, Hunan, China
Contact: Study coordinator (Quchang OuYang, MD) · oyqc1969@126.com

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies

Advanced Solid Tumor · Metastatic Solid Tumor · Refractory Solid Tumor

Abroad (travel likely)RecruitingPHASE1

Sarasota, United States · Boston, United States

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

PIK3CA Mutation · HER2- Negative Breast Cancer · Hormone Receptor Positive Tumor

Abroad (travel likely)RecruitingPHASE3

Gilbert, United States · Beverly Hills, United States

Hypofractionated Irradiation At Regional Nodal Area for Breast Cancer Vs Existed Standard Treatment

Breast Cancer

Abroad (travel likely)RecruitingPHASE3

Shanghai, China

Study of Aerobic Training for People Receiving Treatment for Breast Cancer

Breast Cancer · Breast Carcinoma

Abroad (travel likely)RecruitingPHASE2

Basking Ridge, United States · Middletown, United States